A new tool to predict side effects from the lung cancer drug tarlatamab
Original title: Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer: a multi-institutional real-world analysis
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was a look back at records of people already taking the drug, not a new treatment.
The short version
Doctors looked back at patient records to see who is most likely to get bad side effects from a lung cancer drug.
What was studied. Doctors reviewed the records of 115 people with advanced small cell lung cancer. All of them had been treated with a drug called tarlatamab. The team looked for clues about who had side effects.
What they found. A strong immune reaction happened in 46% of people. Brain or nerve side effects happened in 28%, and taste changes in 47%. More brain tumor spread was linked to a higher chance of brain and nerve problems.
What this means, and what it doesn't
What it could mean: This drug is used for lung cancer, not for tumors that start in the brain. But cancer that had spread to the brain mattered here. People with brain spread may need closer watching while on this drug.
What it doesn't mean: This is not a new treatment and it is not a cure. It was an early look back at past records, not a planned study. The risk tool was only checked against the same group of patients. It has not been tested in new patients, so it is not ready for everyday care.
Source: medRxiv (preprint), October 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.